November 5, 2026

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 [IFRS]

Company name:	Konica Minolta, Inc.
Stock exchange listings:	Tokyo (Prime Market)
Securities code number:	4902
URL:	https://konicaminolta.com
Representative:	Toshimitsu Taiko President and CEO, Representative Executive Officer
Contact:	Koichiro Hattori General Manager, Corporate Accounting Division
Telephone number:	(81) 3-6250-2111
Scheduled date for submission of securities report:	November 11, 2026
Scheduled date for dividends payment:	December 3 , 2026
Availability of supplementary information for the quarterly financial results:	Yes
Organization of briefing on the quarterly financial results:	Yes (for institutional investors)

(Amounts less than one million yen are rounded down to the nearest million yen.)

1. Consolidated financial results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated results of operations

(Percentage figures represent changes from the same period of the previous fiscal year.)

Six months ended	Revenue		Business contribution profit		Operating profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	530,422	3.4	26,367	10.6	22,887	-0.4
September 30, 2025	513,160	-8.0	23,845	45.9	22,982	-

Six months ended	Profit before tax		Profit for the period		Profit attributable to owners of the Company	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	18,593	-7.2	18,211	-22.3	17,790	-21.3
September 30, 2025	20,045	-	23,433	-	22,615	-

Six months ended	Basic earnings per share	Diluted earnings per share
	Yen	Yen
September 30, 2026	35.96	35.88
September 30, 2025	45.76	45.64

(Notes)

1. "Business contribution profit" is calculated by deducting the cost of sales and selling, general and administrative expenses from revenue.
2. Total comprehensive income for the six months ended September 30, 2026 and 2025, was 14,246 million yen (a decrease of 58.2% year-on-year) and 34,122 million yen, respectively.
3. Basic earnings per share and diluted earnings per share are calculated based on the profit attributable to owners of Konica Minolta, Inc. (the "Company").
4. The Precision Medicine Business is classified as a discontinued operation from the three months ended December 31, 2024. As a result, revenue, business contribution profit, operating profit, and profit before tax represent the amount of continuing operations excluding the discontinued operation. Profit for the period and profit attributable to owners of the Company represent the sum of continuing operations and the discontinued operation.

(2) Consolidated financial position

As of	Total assets	Total equity	Equity attributable to owners of the Company	Equity ratio attributable to owners of the Company
	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2026	1,200,541	559,967	546,859	45.6
March 31, 2026	1,234,909	548,971	536,505	43.4

2. Dividends per share

	End of the three-month period	End of the six-month period	End of the nine-month period	End of the year	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	–	5.00	–	7.00	12.00
Fiscal year ending March 31, 2027	–	9.00			
Fiscal year ending March 31, 2027 (forecast)			–	9.00	18.00

(Note) Changes from the latest dividend forecasts: None

3. Consolidated forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentage figures represent changes from the previous fiscal year.)

Fiscal year ending	Revenue		Business contribution profit		Operating profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2027	1,121,000	3.1	57,500	8.1	50,500	1.3

Fiscal year ending	Profit attributable to owners of the Company		Basic earnings per share
	Millions of yen	%	Yen
March 31, 2027	31,500	4.1	63.63

(Note) Changes from the latest consolidated forecasts: Yes

■ Notes

(1) Significant changes in the scope of consolidation for the six months ended September 30, 2026: None

(2) Changes in accounting policies or changes in accounting estimates

a. Changes in accounting policies required by International Financial Reporting Standards (IFRS):	None
b. Changes in accounting policies other than the above a.:	None
c. Changes in accounting estimates:	None

(3) Number of issued and outstanding shares (common stock)

a. Number of issued and outstanding shares (including treasury shares)

As of September 30, 2026:	502,664,337 shares
As of March 31, 2026:	502,664,337 shares

b. Number of treasury shares

As of September 30, 2026:	7,329,708 shares
As of March 31, 2026:	8,480,644 shares

c. Average number of issued and outstanding shares during the period

The six months ended September 30, 2026:	494,763,083 shares
The six months ended September 30, 2025:	494,202,218 shares

(Note) The Company has established the Board Incentive Plan. The shares owned by the trust account relating to this trust are accounted for as treasury shares (1,490,309 shares as of September 30, 2026, and 2,631,462 shares as of March 31, 2026).

■ This summary of interim consolidated financial results falls outside the scope of review procedures to be performed by certified public accountants or an audit firm.

■ Explanation concerning the appropriate use of the forecasts for results of operations and other special matters

Note on the forecasts for the consolidated financial results

The forecasts for results of operations in this report are based on information currently available to the Company and its subsidiaries (the "Group") and certain assumptions determined to be reasonable, and are not intended to assure any achievement of the Group's operations. Actual results may differ significantly from the forecasts due to various factors. For further details of the assumptions that form the basis of the forecasts and other related matters when referring to the forecasts, refer to "1. QUALITATIVE INFORMATION ON FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026, (3) Explanation Regarding the Forecasts for the Consolidated Financial Results" in the attached Supplementary Information on page 13.

Supplementary information for the quarterly financial results and briefing on the quarterly financial results

The Company will hold a briefing on the quarterly financial results for institutional investors on Thursday, November 5, 2026. The proceedings and details of the briefing, along with the supplementary information on the quarterly financial results to be presented at the briefing, will be posted on the website of the Group soon after the briefing.

Supplementary Information

Table of Contents

1. QUALITATIVE INFORMATION ON FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026 6

(1) Qualitative Information on the Consolidated Operating Results 6

(2) Qualitative Information on the Consolidated Financial Position 11

(3) Explanation Regarding the Forecasts for the Consolidated Financial Results 13

2. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES 14

(1) Interim Condensed Consolidated Statements of Financial Position 14

(2) Interim Condensed Consolidated Statements of Profit or Loss 16

(3) Interim Condensed Consolidated Statements of Comprehensive Income 17

(4) Interim Condensed Consolidated Statements of Changes in Equity 18

(5) Interim Condensed Consolidated Statements of Cash Flows 20

(6) Notes to the Interim Condensed Consolidated Financial Statements 22

[Notes Regarding Going Concern Assumptions] 22

[Other Income] 22

[Other Expenses] 22

[Segment Information] 23

[Discontinued Operation] 26

[Additional Information] 27

1. QUALITATIVE INFORMATION ON FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026

(1) Qualitative Information on the Consolidated Operating Results

a. Overview

	Six months ended September 30, 2025	Six months ended September 30, 2026	Increase (Decrease)	
	Billions of yen	Billions of yen	Billions of yen	%
Revenue (Note2)	513.1	530.4	17.2	3.4
Gross profit (Note2)	228.1	250.7	22.5	9.9
Business contribution profit (loss) (Note1) (Note2)	23.8	26.3	2.5	10.6
Operating profit (loss) (Note2)	22.9	22.8	(0)	−0.4
Profit (loss) before tax (Note2)	20.0	18.5	(1.4)	−7.2
Profit (loss) attributable to owners of the Company (Note2)	22.6	17.7	(4.8)	−21.3
	Yen	Yen	Yen	%
Basic earnings (loss) per share (Note2)	45.76	35.96	(9.80)	−21.4
	Billions of yen	Billions of yen	Billions of yen	%
Capital expenditures	36.2	17.8	(18.3)	−50.7
Depreciation and amortization expenses	28.5	31.4	2.8	9.9
Research and development expenses (Note2)	26.7	26.9	0.1	0.6
	Billions of yen	Billions of yen	Billions of yen	%
Free cash flows	11.8	35.7	23.8	200.4
	Number	Number	Number	%
Number of employees in the Group	34,469	34,074	(395)	−1.1
Foreign exchange rates	Yen	Yen	Yen	%
U.S. dollar	146.04	159.37	13.33	9.1
Euro	168.06	184.35	16.29	9.7

(Notes)

1. "Business contribution profit" is calculated by deducting the cost of sales and selling, general and administrative expenses from revenue.
2. The Precision Medicine Business is classified as a discontinued operation from the three months ended December 31, 2024. As a result, revenue, gross profit, business contribution profit, operating profit or loss, profit or loss before tax, and research and development expense represent the amount of continuing operations excluding the discontinued operation. Profit or loss attributable to owners of the Company and basic earnings or loss per share represent the sum of continuing operations and the discontinued operation.

b. Overview by Segment

		Six months ended September 30, 2025	Six months ended September 30, 2026	Increase (Decrease)	
		Billions of yen	Billions of yen	Billions of yen	%
Digital Workplace Business	Revenue	289.4	300.0	10.6	3.7
	Business contribution profit	17.6	16.9	(0.7)	−4.2
	Operating profit	17.1	15.6	(1.5)	−8.8
Professional Print Business	Revenue	123.8	121.6	(2.1)	−1.7
	Business contribution profit	4.8	9.3	4.4	91.9
	Operating profit	2.7	9.0	6.3	225.6
Industry Business	Revenue	59.3	66.1	6.8	11.5
	Business contribution profit	8.9	12.2	3.3	37.3
	Operating profit	8.9	12.1	3.1	35.4
Imaging Solutions Business	Revenue	40.2	42.1	1.9	4.8
	Business contribution profit	0.2	(0.6)	(0.8)	—
	Operating profit	2.0	(2.3)	(4.4)	—
Subtotal	Revenue	512.8	530.0	17.2	3.4
	Business contribution profit	31.7	37.9	6.1	19.5
	Operating profit	30.9	34.4	3.5	11.5
Others and Adjustments (Note 2)	Revenue	0.3	0.3	0	12.9
	Business contribution profit	(7.8)	(11.5)	(3.6)	—
	Operating profit	(7.9)	(11.5)	(3.6)	—
Amount Reported in the Interim Condensed Consolidated Statements of Profit or Loss	Revenue	513.1	530.4	17.2	3.4
	Business contribution profit	23.8	26.3	2.5	10.6
	Operating profit	22.9	22.8	(0)	−0.4

(Notes)

1. "Revenue" refers to revenue from external customers.
2. "Revenue" refers to revenue from external customers in "Others" in "2. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES, (6) Notes to the Interim Condensed Consolidated Financial Statements, [Segment Information]." "Operating profit" is the sum of "Others" and "Adjustments" in segment profit (loss) within the same table.
3. The Precision Medicine Business is classified as a discontinued operation from the three months ended December 31, 2024. Accordingly, the amounts presented represent continuing operations excluding the discontinued operation.
4. Effective from the current fiscal year, certain businesses previously included in the "Imaging Solutions Business" have been reclassified, including video solution services to the "Digital Workplace Business" and gas monitoring solutions to the "Industry Business," to reflect changes in the actual management structure. Accordingly, figures for the previous fiscal year have also been disclosed based on figures after reflecting these changes.

Under the "Corporate Plan 2026–2028," the Company has positioned the three-year period as a phase to build a foundation for long-term growth. The current fiscal year ending March 31, 2027, which is the first year, the Company focused on profit growth centered on the Industry Business and Professional Print

Business, strengthening of financial structure, and commercialization of growth seeds.

During the six months ended September 30, 2026 (the "current period"), the Group's consolidated revenue amounted to 530.4 billion yen (an increase of 3.4% year-on-year). This is due to the contribution of increase in revenue year on year of the Digital Workplace Business, the Industry Business, and the Imaging Solutions Business supported by the impact of yen depreciation in exchange rates.

Gross profit amounted to 250.7 billion yen (an increase of 9.9% year-on-year). Although the deteriorating business environment, including the impact of the situation in the Middle East, higher procurement costs for components such as semiconductors and electronic parts, and higher price of silver, had a negative impact on profit of approximately 1.5 billion yen, gross profit increased in all businesses, led primarily by the Industry Business, which performed well. The figure also includes 11.9 billion yen refunds related to U.S. tariff expenses recorded in the previous fiscal year.

Selling, general and administrative expenses amounted to 224.3 billion yen (an increase of 9.8% year-on-year), reflecting such as the impact of foreign exchange rates, as well as higher expenses in the Digital Workplace Business and the absence of one-time factors that reduced expenses recorded in the same period of the previous fiscal year.

As a result, business contribution profit was 26.3 billion yen (an increase of 10.6% year-on-year).

Operating profit was 22.8 billion yen (a decrease of 0.4% year-on-year). Business structure improvement expenses of 1.8 billion yen related to the overseas Digital Workplace Business and the Professional Print Business (compared to 0.5 billion yen in the same period of the previous fiscal year) were recorded as other expenses. In addition, the Company recorded a loss on sales and disposals of property, plant and equipment and intangible assets of 1.4 billion yen (compared to 0.4 billion yen in the same period of the previous fiscal year), mainly due to the termination of certain businesses in the imaging-IoT solutions unit of the Imaging Solutions Business.

The summary of revenue, business contribution profit, and operating profit of each business is as follows:

i. Digital Workplace Business

Revenue of the Digital Workplace Business was 300.0 billion yen (an increase of 3.7% year-on-year).

Revenue of the office unit increased year-on-year due to the effect of yen depreciation in exchange rates. The hardware (sales of equipment) revenue increased due to the effect of yen depreciation in exchange rates. Excluding foreign exchange effects, hardware revenue decreased in North America, mainly due to deteriorating market conditions and the absence of large contracts recorded in the same period and also decreased in Asia. The non-hardware (consumables, services, and others) revenue increased due to the effect of yen depreciation in exchange rates. Excluding foreign exchange effects, revenue decreased mainly in Europe and the United States due to a decline in the amount of equipment in operation in the market.

In the DW-DX unit, which mainly offers services, such as IT services, revenue increased year-on-year. In addition to the effect of yen depreciation, the services to manage business content and operation processes progressed in the United States, Europe, and Japan, and in-house-developed AI SaaS business, such as AI-based learning support services and others, grew in Japan. Revenue of the managed IT services decreased year-on-year as a result of a decline in demand for PC replacements following the end of support for Windows 10, as well as the transfer of certain businesses as part of the business selection and concentration implemented in the same period of the previous fiscal year

The business contribution profit of the Digital Workplace Business was 16.9 billion yen (a decrease of 4.2% year-on-year). In the office unit, despite the impact of the situation in the Middle East and higher procurement costs for components such as semiconductors and electronic parts, gross profit increased benefiting from the effect of yen depreciation in exchange rates and the aforementioned U.S. tariff refunds. However, the business contribution profit decreased due to an increase in selling, general and administrative expenses such as research and development expenses.

Operating profit was 15.6 billion yen (a decrease of 8.8% year-on-year). As part of other expenses, the aforementioned business structure improvement expenses were recorded with the aim of improving the profitability of the office unit.

ii. Professional Print Business

Revenue of the Professional Print Business was 121.6 billion yen (a decrease of 1.7% year-on-year).

Revenue in the production print unit decreased year-on-year. This was affected by a decrease of revenue due to the transfer of shares of Konica Minolta Marketing Services Holding Company Limited, which was

implemented in the same period of the previous fiscal year as part of business selection and concentration. Excluding this impact, however, revenue increased, supported by the positive effect of yen depreciation. Hardware revenue decreased. Despite the positive effect of yen depreciation, revenue from fast print speed Heavy Production Print (HPP) and Mid Production Print (MPP) decreased due to subdued client's appetite for investment. Regionally, revenue decreased in Europe, the United States, and China. Non-hardware revenue increased, reflecting the positive effect of yen depreciation as well as an increase in the installed base of HPP. Regionally, revenue decreased in Europe and China, while increased in the United States, India, and other regions.

Revenue in the industrial print unit increased year-on-year. In addition to the positive effect of yen depreciation, revenue of hardware and non-hardware increased due to the increased sales volume of label press and embellishment printing equipment.

The business contribution profit of the Professional Print Business was 9.3 billion yen (an increase of 91.9% year-on-year). Gross profit increased benefiting from yen depreciation and the aforementioned U.S. tariff refunds.

Operating profit was 9.0 billion yen (an increase of 225.6% year-on-year). This increase also reflected the absence of 2.1 billion yen in expenses related to the transfer of shares of Konica Minolta Marketing Services Holding Company Limited, which were recognized in the same period of the previous fiscal year.

iii. Industry Business

Revenue of the Industry Business was 66.1 billion yen (an increase of 11.5% year-on-year).

Revenue in the sensing unit increased year-on-year. Sales of light source color measurement instruments increased due to increased capital investments in displays by major customers. The revenue from object color measurement instruments increased due to the steady sales of software and services. Sales of measurement instruments applying hyperspectral imaging technology, a growth domain, increased due to steady orders for applications such as mineral mining and recycling. Sales of testing equipment for automotive visual inspections performed well, by strengthening solutions for parts suppliers, on which the Company focuses.

In the performance materials unit, revenue decreased year-on-year. In the large-sized area, such as TVs, sales of TAC films with improved high transparency and SANUQI, a new-generation COP film suitable for large panels, remained steady. However, revenue decreased in the current period because production capacity limitations in the previous fiscal year resulted in insufficient inventory levels in the three months ended June 30, 2026. Inventory levels recovered in the current period.

In the inkjet (IJ) components unit, revenue increased year-on-year. Sales performed well in the sign graphics market due to recovering demand and increased sales of new two-color ink products launched in the previous fiscal year. In addition, business other than IJ printhead and ink performed well.

In the optical components unit, revenue increased year-on-year. Interchangeable lenses for camera performed well driven by the increasing demand. Sales of optical components for semiconductor inspection equipment, on which the Company focuses, remained steady supported by the increasing demand due to chiplet integration and by the expansion of production capacity to meet the demand.

The business contribution profit of the Industry Business amounted to 12.2 billion yen (an increase of 37.3% year-on-year). This was supported by the growth in gross profit due to higher sales in the sensing unit, the IJ components unit, and the optical components unit, as well as a reduction in selling, general and administrative expenses in the performance materials unit.

Operating profit was 12.1 billion yen (an increase of 35.4% year-on-year).

iv. Imaging Solutions Business

The Imaging Solutions Business recorded a revenue of 42.1 billion yen (an increase of 4.8% year-on-year).

The healthcare unit saw an increase in revenue year-on-year due to the effect of yen depreciation. DR (Digital Radiography) grew due to the increased sales to other companies' brands and sales in India and Japan. X-ray film saw an increase in India, in addition to an easing of the decline in demand in China. Healthcare IT performed well in the United States. Meanwhile, sales of purchased products in Japan decreased.

The visual solutions unit saw an increase in revenue year-on-year mainly due to the steady performance of directly managed planetariums.

The imaging IoT solutions unit terminated the sale of FORXAI Video Vision in Europe and also proceeded with preparations for the termination of its remaining businesses in certain regions.

The business contribution loss was 0.6 billion yen (the business contribution profit was 0.2 billion yen in

the same period of the previous fiscal year). The business contribution loss was recorded mainly due to the spike in the price of silver, a raw material, in the healthcare unit.

Operating loss was 2.3 billion yen (the profit was 2.0 billion yen in the same period of the previous fiscal year). This was due to the absence of gain on sales of subsidiaries associated with the transfer of equity capital of MOBOTIX AG recorded in the same period of the previous fiscal year, as well as a loss on sales and disposals of property, plant and equipment and intangible assets recognized in the imaging IoT solutions unit.

The Group's profit before tax for the current period was 18.5 billion yen (a decrease of 7.2% year-on-year). Financial balance has deteriorated by 1.3 billion yen year-on-year mainly due to the absence of gains on the acquisition of real estate trust beneficiary interests recorded in the same period of the previous fiscal year, as well as an increase in interest expenses and foreign exchange losses.

The profit from continuing operations was 13.5 billion yen (a decrease of 10.3% year-on-year). Tax expenses remained flat year-on-year. This was due to the improved profitability in U.S. subsidiaries benefiting from the refunds related to tariff expenses, as well as a decline in effective tax rate, mainly due to a lower tax burden by utilizing loss carryforwards and an improvement resulting from differences in overseas tax rates. The profit from discontinued operations was 4.6 billion yen (a decrease of 43.9% year-on-year). In addition to the recognition of a profit of 2.9 billion yen, which was a gain from the sale of the shares of Tempus AI, Inc ("Tempus") received as consideration for the transfer of shares of Ambry Genetics Corporation ("Ambry Genetics"), a gain of 1.8 billion yen associated with the settlement of the escrow holdback related to the sale of equity capital in Invicro, LLC is recorded. Meanwhile, an 8.3 billion yen in gain recorded in the same period of the previous fiscal year, mainly from the fair value remeasurement and partial sale of Tempus shares, was absent. The Company has sold all Tempus shares it held in June 2026. The profit attributable to owners of the Company was 17.7 billion yen (a decrease of 21.3% year-on-year).

(2) Qualitative Information on the Consolidated Financial Position

a. Analysis of Consolidated Financial Position

	As of March 31, 2026	As of September 30, 2026	Increase (Decrease)
	Billions of yen	Billions of yen	Billions of yen
Total assets	1,234.9	1,200.5	(34.3)
Total liabilities	685.9	640.5	(45.3)
Total equity	548.9	559.9	10.9
Equity attributable to owners of the Company	536.5	546.8	10.3
	%	%	%
Equity ratio attributable to owners of the Company	43.4	45.6	2.2

Total assets as of September 30, 2026, were 1,200.5 billion yen, a decrease of 34.3 billion yen (2.8%) from March 31, 2026. This is primarily attributed to a decrease of 23.6 billion yen in trade and other receivables, a decrease of 13.3 billion yen in cash and cash equivalents, a decrease of 8.3 billion yen in other financial assets, and an increase of 8.7 billion yen in inventories.

Total liabilities as of September 30, 2026, were 640.5 billion yen, a decrease of 45.3 billion yen (6.6%) from March 31, 2026. This is primarily attributed to a decrease of 31.7 billion yen in bonds and borrowings, a decrease of 11.5 billion yen in trade and other payables, and a decrease of 2.0 billion yen in other current liabilities.

Total equity as of September 30, 2026, was 559.9 billion yen, an increase of 10.9 billion yen (2.0%) from March 31, 2026.

Equity attributable to owners of the Company was 546.8 billion yen as of September 30, 2026, an increase of 10.3 billion yen (1.9%) from March 31, 2026. This is primarily attributed to a decrease of 4.3 billion yen in other components of equity (primarily exchange differences on translation of foreign operations) and the recording of a profit attributable to owners of the Company of 17.7 billion yen.

As a result of the above, the equity ratio attributable to owners of the Company increased by 2.2 percentage points to 45.6%.

b. Analysis of Consolidated Cash Flows

	Six months ended September 30, 2025	Six months ended September 30, 2026	Increase (Decrease)
	Billions of yen	Billions of yen	Billions of yen
Cash flows from operating activities	25.0	38.9	13.9
Cash flows from investing activities	(13.1)	(3.2)	9.9
Total (free cash flows)	11.8	35.7	23.8
Cash flows from financing activities	(12.4)	(49.3)	(36.9)

For the six months ended September 30, 2026, net cash provided by operating activities was 38.9 billion yen, and net cash used in investing activities totaled 3.2 billion yen. As a result, free cash flows (the sum of cash flows from operating activities and investing activities) were an inflow of 35.7 billion yen for the current period.

Net cash used in financing activities was 49.3 billion yen.

In addition, cash and cash equivalents as of September 30, 2026, decreased by 13.3 billion yen from March 31, 2026, to 97.4 billion yen, reflecting the effect of exchange rate fluctuations on cash and cash equivalents.

Cash flows from operating activities

Net cash provided by operating activities was 38.9 billion yen. On top of the profit before tax of 18.5 billion yen and profit before tax from discontinued operation of 4.6 billion yen, this is attributable to the net effects of cash inflows mainly due to depreciation and amortization expenses of 31.4 billion yen and a decrease in trade and other receivables of 20.0 billion yen; and cash outflows mainly due to an increase in inventory of 11.5 billion yen, a decrease in trade and other payables of 5.4 billion yen, interest paid of 5.6 billion yen, and income tax paid of 5.3 billion yen.

In addition, cash flows from operating activities include the impact of refunds related to U.S. tariff expenses recorded in the previous fiscal year.

Cash flows from investing activities

Net cash used in investing activities was 3.2 billion yen, mainly due to the purchase of the property, plant and equipment of 12.8 billion yen, the purchase of intangible assets of 6.5 billion yen, and proceeds from sales of investment securities of 16.1 billion yen.

In addition, proceeds from sales of investment securities include proceeds from the sale of the Tempus shares received as consideration for the transfer of shares of Ambry Genetics.

As a result, free cash flows (the sum of cash flows from operating activities and investing activities) were an inflow of 35.7 billion yen (an inflow of 11.8 billion yen for the same period in the previous fiscal year).

Cash flows from financing activities

Net cash used in financing activities was 49.3 billion yen (net cash outflows of 12.4 billion yen for the same period in the previous fiscal year), reflecting cash outflows of a net decrease in short-term loans payable of 36.9 billion yen, repayments of lease liabilities of 10.5 billion yen, cash dividends paid of 3.3 billion yen, and cash inflows of bonds issuance and long-term loans payable of 3.1 billion yen.

(3) Explanation Regarding the Forecasts for the Consolidated Financial Results

With respect to the full-year forecasts, the Company expects an increase in revenue, reflecting the positive effect of yen depreciation. The Company reflects the positive impact on profit from the U.S. tariff refunds, which had not been incorporated into the forecasts announced on May 14, 2026, as well as the progress for the six months ended September 30, 2026. In addition, while the Company expects the Industry Business to continue to perform well and the Professional Print Business to grow, it also factored in the impact of the deteriorating business environment, including the prolonged effects of the situation in the Middle East and rising procurement costs for components such as semiconductors and electronic parts. In response to these changes in the business environment, the Company has factored in costs associated with accelerated implementation of profitability improvement initiatives that had been planned for FY2027 under the Medium-term Business Plan. Furthermore, taking into account factors including profit from the sale of Tempus shares in discontinued operation, the Company has decided to change its full-year forecasts from those announced on July 30, 2026.

The assumed exchange rates from the third quarter onward remain unchanged at 150 yen to the U.S. dollar and 180 yen to the euro.

Revision of consolidated financial forecasts for the fiscal year ending March 31, 2027
(April 1, 2026 to March 31, 2027)

	Revenue (Note 2)	Business contribution profit (Note 1) (Note 2)	Operating profit (loss) (Note 2)	Profit attributable to owners of the Company (loss) (Note 2)	Basic earnings per share (loss) (Note 2)
Forecasted previously announced (A)	Billions of yen 1,105.0	Billions of yen 56.0	Billions of yen 50.0	Billions of yen 28.5	Yen 57.57
Revised forecasts (B)	1,121.0	57.5	50.5	31.5	63.63
Increase / decrease (B-A)	16.0	1.5	0.5	3.0	6.06
Change (%)	1.4	2.7	1.0	10.5	10.5
(Reference) Results for the fiscal year ended March 31, 2026	1,087.7	53.1	49.8	30.2	61.25

(Notes)

1. The profit measure that is calculated by deducting cost of sales and selling, general and administrative expenses from revenue.
2. The Precision Medicine Business has been classified as a discontinued operation from the third quarter ended December 31, 2024. As a result, in the consolidated forecasts, revenue, business contribution profit, and operating profit represent the amount of continuing operations, and profit attributable to owners of the Company and basic earnings per share represent the sum of continuing operations and the discontinued operation. In addition, the changes from the previous fiscal year have been calculated using the retrospectively revised figures associated with the classification of the discontinued operation.

* The above forecasts for the results of operations are based on suppositions, outlooks, and plans as of the release date of this report and as such, they involve risks and uncertainties. Actual results may differ significantly from these forecasts due to various important factors, such as changes in economic conditions, market trends, and currency exchange rates.

Amounts in "1. QUALITATIVE INFORMATION ON FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026" are rounded down to the nearest stated unit.

2. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES

(1) Interim Condensed Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and cash equivalents	110,762	97,409
Trade and other receivables	316,640	292,990
Inventories	210,467	219,202
Income tax receivables	3,562	2,100
Other financial assets	14,122	2,945
Other current assets	37,461	39,642
Total current assets	693,017	654,289
Non-current assets		
Property, plant and equipment	259,533	260,993
Goodwill and intangible assets	182,775	180,018
Investments accounted for using the equity method	1,086	1,031
Other financial assets	23,601	26,432
Deferred tax assets	28,235	30,539
Other non-current assets	46,659	47,235
Total non-current assets	541,892	546,251
Total assets	1,234,909	1,200,541

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Trade and other payables	172,737	161,164
Bonds and borrowings	113,670	97,962
Lease liabilities	19,962	17,335
Income tax payables	6,481	8,113
Provisions	14,114	12,697
Other financial liabilities	2,088	218
Other current liabilities	65,540	63,500
Total current liabilities	394,596	360,992
Non-current liabilities		
Bonds and borrowings	215,969	199,879
Lease liabilities	48,709	53,295
Retirement benefit liabilities	15,688	14,975
Provisions	4,039	4,187
Other financial liabilities	873	1,041
Deferred tax liabilities	2,957	2,955
Other non-current liabilities	3,104	3,245
Total non-current liabilities	291,342	279,580
Total liabilities	685,938	640,573
Equity		
Share capital	37,519	37,519
Share premium	203,664	203,417
Retained earnings	145,680	160,103
Treasury shares	(8,894)	(8,335)
Share acquisition rights	158	150
Other components of equity	158,377	154,002
Equity attributable to owners of the Company	536,505	546,859
Non-controlling interests	12,466	13,108
Total equity	548,971	559,967
Total liabilities and equity	1,234,909	1,200,541

(2) Interim Condensed Consolidated Statements of Profit or Loss

Six months ended September 30, 2025 and 2026

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Continuing Operations		
Revenue	513,160	530,422
Cost of sales	284,992	279,670
Gross profit	228,167	250,751
Other income	4,936	1,865
Selling, general and administrative expenses	204,321	224,383
Other expenses	5,800	5,345
Operating profit (loss)	22,982	22,887
Finance income	2,641	2,630
Finance costs	5,578	6,867
Share of profit (loss) of investments accounted for using the equity method	(0)	(57)
Profit (loss) before tax	20,045	18,593
Income tax expense (income)	4,961	5,064
Profit (loss) from continuing operations	15,083	13,528
Discontinued Operation		
Profit (loss) from discontinued operation	8,349	4,682
Profit (loss) for the period	23,433	18,211
Profit (loss) attributable to:		
Owners of the Company	22,615	17,790
Non-controlling interests	817	420
Earnings (loss) per share	Yen	Yen
Basic	45.76	35.96
Continuing operations	28.90	26.49
Discontinued operation	16.87	9.46
Diluted	45.64	35.88
Continuing operations	28.82	26.43
Discontinued operation	16.82	9.44

(3) Interim Condensed Consolidated Statements of Comprehensive Income

Six months ended September 30, 2025 and 2026

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit (loss) for the period	23,433	18,211
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Remeasurements of defined benefit pension plans (net of tax)	(475)	34
Net gain (loss) on revaluation of financial assets measured at fair value (net of tax)	660	2,377
Total items that will not be reclassified to profit or loss	184	2,412
Items that may be subsequently reclassified to profit or loss		
Net gain (loss) on derivatives designated as cash flow hedges (net of tax)	60	35
Exchange differences on translation of foreign operations (net of tax)	10,435	(6,422)
Share of other comprehensive income of investments accounted for using the equity method (net of tax)	8	9
Total items that may be subsequently reclassified to profit or loss	10,504	(6,377)
Total other comprehensive income (loss)	10,689	(3,964)
Total comprehensive income (loss)	34,122	14,246
Total comprehensive income (loss) attributable to:		
Owners of the Company	33,044	13,514
Non-controlling interests	1,077	731

(4) Interim Condensed Consolidated Statements of Changes in Equity

(Millions of yen)

	Share capital	Share premium	Retained earnings	Treasury shares	Share acquisition rights	Other components of equity	Equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2025	37,519	203,899	116,401	(8,652)	188	113,798	463,154	10,924	474,079
Profit (loss) for the period	—	—	22,615	—	—	—	22,615	817	23,433
Other comprehensive income (loss)	—	—	—	—	—	10,429	10,429	260	10,689
Total comprehensive income (loss)	—	—	22,615	—	—	10,429	33,044	1,077	34,122
Dividends	—	—	—	—	—	—	—	(254)	(254)
Acquisition and disposal of treasury shares	—	—	(7)	(268)	—	—	(276)	—	(276)
Share-based payments	—	(5)	—	—	(19)	—	(24)	—	(24)
Changes in the scope of consolidation	—	—	—	—	—	—	—	(348)	(348)
Changes in ownership interests in subsidiaries	—	(89)	—	—	—	—	(89)	(176)	(266)
Equity and other transactions with non-controlling shareholders	—	(119)	—	—	—	—	(119)	—	(119)
Transfer from other components of equity to retained earnings	—	—	(415)	—	—	415	—	—	—
Total transactions with owners	—	(214)	(422)	(268)	(19)	415	(509)	(780)	(1,289)
Balance as of September 30, 2025	37,519	203,684	138,594	(8,921)	169	124,642	495,689	11,222	506,912

(Millions of yen)

	Share capital	Share premium	Retained earnings	Treasury shares	Share acquisition rights	Other components of equity	Equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2026	37,519	203,664	145,680	(8,894)	158	158,377	536,505	12,466	548,971
Profit (loss) for the period	—	—	17,790	—	—	—	17,790	420	18,211
Other comprehensive income (loss)	—	—	—	—	—	(4,276)	(4,276)	311	(3,964)
Total comprehensive income (loss)	—	—	17,790	—	—	(4,276)	13,514	731	14,246
Dividends	—	—	(3,459)	—	—	—	(3,459)	(90)	(3,549)
Acquisition and disposal of treasury shares	—	—	(6)	559	—	—	552	—	552
Share-based payments	—	(252)	—	—	(7)	—	(260)	—	(260)
Equity and other transactions with non-controlling shareholders	—	6	—	—	—	—	6	—	6
Transfer from other components of equity to retained earnings	—	—	98	—	—	(98)	—	—	—
Total transactions with owners	—	(246)	(3,367)	559	(7)	(98)	(3,160)	(90)	(3,250)
Balance as of September 30, 2026	37,519	203,417	160,103	(8,335)	150	154,002	546,859	13,108	559,967

(5) Interim Condensed Consolidated Statements of Cash Flows

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit (loss) before tax	20,045	18,593
Profit (loss) before tax from discontinued operation	8,312	4,670
Depreciation and amortization expense	28,569	31,403
Impairment losses and reversal of impairment losses	439	480
Interest and dividends income	(1,537)	(2,627)
Interest expenses	5,373	6,087
(Gain) loss on sales and disposals of property, plant and equipment, and intangible assets	(134)	1,311
(Increase) decrease in trade and other receivables	16,724	20,060
(Increase) decrease in inventories	(11,181)	(11,514)
Increase (decrease) in trade and other payables	(10,500)	(5,438)
Decrease due to transfer of rental assets	(2,545)	(2,548)
Increase (decrease) in retirement benefit liabilities	(453)	(2,880)
Others	(19,063)	(10,040)
Subtotal	34,048	47,557
Dividends received	190	219
Interest received	1,427	2,178
Interest paid	(5,267)	(5,666)
Income taxes (paid) refunded	(5,339)	(5,313)
Net cash provided by (used in) operating activities	25,058	38,975

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from investing activities		
Purchase of property, plant and equipment	(30,014)	(12,869)
Purchase of intangible assets	(6,095)	(6,535)
Proceeds from sales of property, plant and equipment, and intangible assets	2,887	682
Proceeds from sales of subsidiaries	5,749	159
Payments for sales of subsidiaries	(1,223)	—
Proceeds from sales of investment securities	17,118	16,121
Payments for transfer of business	(241)	—
Payments for acquisition of business	—	(311)
Others	(1,339)	(471)
Net cash provided by (used in) investing activities	(13,158)	(3,224)
Cash flows from financing activities		
Increase (decrease) in short-term loans payable	(1,317)	(36,960)
Proceeds from bonds issuance and long-term loans payable	348	3,122
Redemption of bonds and repayments of long-term loans payable	(207)	(1,545)
Repayments of lease liabilities	(10,383)	(10,583)
Cash dividends paid	(2)	(3,330)
Payment of dividends to non-controlling shareholders	(259)	(90)
Payment for purchases of investments in subsidiaries with no changes in scope of consolidation	(266)	—
Others	(325)	(0)
Net cash provided by (used in) financing activities	(12,413)	(49,389)
Effect of exchange rate changes on cash and cash equivalents	1,239	284
Net increase (decrease) in cash and cash equivalents	725	(13,353)
Cash and cash equivalents at the beginning of the period	92,887	110,762
Cash and cash equivalents at the end of the period	93,612	97,409

(6) Notes to the Interim Condensed Consolidated Financial Statements

[Notes Regarding Going Concern Assumptions]

Not Applicable.

[Other Income]

Components of other income are as follows:

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Gain on sales of shares in subsidiaries	2,268	-
Others	2,667	1,865
Total	4,936	1,865

[Other Expenses]

Components of other expenses are as follows:

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Business structure improvement expenses	509	1,876
Loss on sales and disposals of property, plant and equipment, and intangible assets	465	1,408
Loss on sales of shares in subsidiaries	2,155	-
Others	2,669	2,060
Total	5,800	5,345

[Segment Information]

(a) Reportable segments

Operating segments of the Group are its components for which separate financial data is available and that are examined on a regular basis for the purpose of enabling the Group's management to decide on the allocation of resources and evaluate the results of operations. The Group has established business units by product and service category and formulates comprehensive strategies and conducts business activities in Japan and overseas for the products and services of each business unit.

The Group comprises operating segments organized by product and service category based on each business unit, and based on the operating segments, the Group established four reportable segments as the "Digital Workplace Business," "Professional Print Business," "Industry Business," and "Imaging Solutions Business" while taking into account the primary usage of products of the respective businesses in the markets and their similarities.

Effective from the current fiscal year, certain businesses previously included in the "Imaging Solutions Business" have been reclassified, including video solution services to the "Digital Workplace Business" and gas monitoring solutions to the "Industry Business," to reflect changes in the actual management structure. Accordingly, figures for the previous fiscal year have also been disclosed based on figures after reflecting these changes.

Businesses of each reportable segment are described as follows:

		Business content
Business Technologies Business (Note)	Digital Workplace Business	Office Development, manufacture, and sales of MFPs and related consumables; provision of related services and solutions
		DW-DX Provision of IT services and solutions
	Professional Print Business	Production Print Development, manufacture, and sales of digital printing systems and related consumables for the commercial printing market; provision of various printing services and solutions
		Industrial Print Development, manufacture, and sales of digital printing systems and related consumables for the industrial printing market
Industry Business		Sensing Development, manufacture, and sales of measuring instruments and others; provision of related solutions and services
		Performance Materials Development, manufacture, and sales of functional films for displays and others
		Inkjet (IJ) Components Development, manufacture, and sales of industrial inkjet printheads and others
		Optical Components Development, manufacture, and sales of lenses for industrial and professional use and others
Imaging Solutions Business		Healthcare Development, manufacture, and sales of diagnostic imaging systems for medical use; provision of related services; provision of digitalization, networking, diagnostic services, and solutions in medical field
		Imaging-IoT Solutions Provision of solutions and services centered on network cameras
		Visual Solutions Development, manufacture, and sales of visual-related equipment; provision of related solutions and services
		QOL Solutions Development, sales, and consulting of products, information systems, and services related to nursing care services

(Note) It is the name of an internal organization that manages the Digital Workplace Business and the Professional Print Business.

(b) Information by reportable segment

Information by reportable segment of the Group is as follows. Segment profit refers to the operating profit of the segment.

Six months ended September 30, 2025

(Millions of yen)

	Reportable segments					Others	Adjustments (Note 2) (Note 3)	Total
	Business Technologies Business		Industry Business	Imaging Solutions Business	Total			
	Digital Workplace Business	Professional Print Business						
Revenue								
External	289,435	123,834	59,321	40,263	512,854	305	—	513,160
Intersegment (Note 1)	1,713	14	2,200	424	4,352	6,590	(10,943)	—
Total	291,149	123,848	61,521	40,688	517,207	6,896	(10,943)	513,160
Segment profit (loss)	17,136	2,793	8,967	2,016	30,914	98	(8,031)	22,982

Six months ended September 30, 2026

(Millions of yen)

	Reportable segments					Others	Adjustments (Note 2) (Note 3)	Total
	Business Technologies Business		Industry Business	Imaging Solutions Business	Total			
	Digital Workplace Business	Professional Print Business						
Revenue								
External	300,042	121,692	66,155	42,186	530,077	345	—	530,422
Intersegment (Note 1)	1,878	12	2,359	297	4,547	6,791	(11,339)	—
Total	301,921	121,705	68,514	42,484	534,625	7,136	(11,339)	530,422
Segment profit (loss)	15,634	9,095	12,145	(2,398)	34,478	374	(11,964)	22,887

(Notes)

1. Intersegment revenue is based on market prices and others.
2. Adjustments of revenue are elimination of intersegment transactions.
3. Adjustments of segment profit are elimination of intersegment transactions and corporate expenses, which consist of general and administrative expenses and basic research expenses not attributable to any of the reportable segments or “Others.” They include other income and other expenses not attributable to any of the reportable segments.

[Discontinued Operation]

(a) Outline of the discontinued operation

The Group completed the transfer of all equity capital of Invicro, LLC to Calyx Services Inc. on April 30, 2024. In addition, on February 3, 2025, the Group completed to transfer all shares of Ambry Genetics to Tempus. As a result, the Precision Medicine Business is classified as a discontinued operation, and profit or loss from discontinued operation is presented separately from continuing operations in the interim condensed consolidated statements of profit or loss.

(b) Profit or loss from discontinued operation

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Discontinued Operation		
Income (Note 1)	10,019	4,882
Expenses (Note 2)	1,707	212
Profit (loss) before tax from discontinued operation	8,312	4,670
Income tax expense	(36)	(11)
Profit (loss) from discontinued operation	8,349	4,682

(Notes)

1. During the six months ended September 30, 2025, the sum of a loss which was recognized as a result of the realization of the partial sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics and a profit which was recognized as a result of the changes in the fair value of the shares of 8,422 million yen, is included.
   During the six months ended September 30, 2026, a profit of 2,916 million yen, which was recognized as a result of the realization of the sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics, is included. The Company has sold all Tempus shares it held.
2. During the six months ended September 30, 2025, a loss of 113 million yen is included, which was recognized as a result of the transfer of all the shares of Konica Minolta REALM Inc.

(c) Profit attribution

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Owners of the Company		
Profit (loss) from continuing operations	14,280	13,108
Profit (loss) from discontinued operation	8,334	4,682
Total	22,615	17,790
Non-controlling interests		
Profit (loss) from continuing operations	803	420
Profit (loss) from discontinued operation	14	—
Total	817	420

(d) Cash flows from discontinued operation

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities	(2,514)	251
Cash flows from investing activities (Note)	17,620	15,958
Cash flows from financing activities	(266)	—
Total	14,839	16,209

(Note) During the six months ended September 30, 2025, proceeds from sale of investment securities of 16,966 million yen, which was a result of the realization of the partial sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics, are included. In addition, proceeds of 394 million yen from the sale of a subsidiary are included. The breakdown of assets and liabilities at the time of the sale of shares resulting in loss of control over the subsidiary is cash and cash equivalents of 205 million yen, total assets of 1,713 million yen, and total liabilities of 482 million yen.

During the six months ended September 30, 2026, proceeds from sale of investment securities of 15,958 million yen, which was a result of the realization of the sale of Tempus shares received as consideration in connection with the share transfer of Ambry Genetics, are included.

[Additional Information]

Status of Refund Procedures Related to U.S. Tariffs

Following the ruling that tariffs imposed in the United States under the International Emergency Economic Powers Act ("IEEPA") were invalid, certain U.S. subsidiaries of the Group filed claims with U.S. Customs and Border Protection ("CBP") for refunds of the relevant tariffs.

As of the six months ended September 30, 2026, the Group has received refunds totaling 74 million U.S. dollars (approximately 11.9 billion yen). The refund amount is deducted from cost of sales in the Interim Condensed Consolidated Financial Statements.